Clinical course and background of eight patients who discontinued secukinumab after achieving a score of 0 on the psoriasis area and severity index

J Dermatol. 2021 Aug;48(8):e380-e381. doi: 10.1111/1346-8138.15948. Epub 2021 May 18.

Authors

Masahito Yasuda¹, Naoko Morimoto¹, Yuta Inoue¹, Osamu Ishikawa¹, Sei-Ichiro Motegi¹

Affiliation

¹ Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.

PMID: 34002889
DOI: 10.1111/1346-8138.15948

No abstract available

Keywords: disease modification; psoriasis; psoriasis area and severity index score; relapse; secukinumab.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized*
Double-Blind Method
Humans
Psoriasis* / diagnosis
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
secukinumab